Translational Research Decision Tree

What are you developing?

Is the research fundamental basic or applied research that uses existing market approved devices for their labeled use?

Are you proposing a clinical trial?

Are you proposing only clinical work?

Consider:

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3) (RFA-NS-18-023)  

Exploratory Clinical Trials (U01) (PAR-18-420

SBIR/STTR Exploratory Clinical Trials (R42) (PAR-18-617

NeuroNEXT Clinical Trials (U01) (PAR-18-528) or (U44) (PAR-18-628

StrokeNET Clinical Trials and Biomarker Studies (U01) (PAR-18-561) or (U44) (PAR-18-563

Bioengineering Research Grants (R01) (PAR-18-206)

Bioengineering Research Partnerships (U01) (PAR-18-208)

Are you proposing a clinical trial?

Consider:

Bioengineering Research Grants (R01) (PAR-18-206)

Bioengineering Research Partnerships (U01) (PAR-18-208)

SBIR/STTR Omnibus Solicitations

Consider:

Translational Neural Devices (UG3/UH3) (RFA-NS-18-011) or (U44) (RFA-NS-18-012

BRAIN Initiative:
Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3) (RFA-NS-18-021) or (U44) (RFA-NS-18-022

Bioengineering Research Grants (R01) (PAR-18-206)

Bioengineering Research Partnerships (U01) (PAR-18-208)

Consider:

Exploratory Clinical Trials (U01) (PAR-18-420

NeuroNEXT Clinical Trials (U01) (PAR-18-528

Do you have a compound that shows promising activity in a disease model?

Can you fill out our Compound Profile Table, with no liabilities?

Are you a small business?

Consider the Blueprint Neurotherapeutics Network SBIR U44 award (PAR-17-201), with entry at the Development stage.
Email Dr. Charles Cywin to confirm.

Consider the IGNITE Program for small throughput assay development.

Do you have assays that can be used or optimized for structure activity relationship (SAR) studies?

Consider the Blueprint Neurotherapeutics Network UG3/UH3 award (PAR-17-205), with entry at the Development stage.
Email Dr. Charles Cywin to confirm.

Consider the IGNITE Program for small throughput assay development.

Are you a small business?

Consider the Blueprint Neurotherapeutics Network SBIR U44 award (PAR-17-201), with entry at the Discovery stage.
Email Dr. Charles Cywin to confirm.

Consider the Blueprint Neurotherapeutics Network UG3/UH3 award (PAR-17-205), with entry at the Discovery stage.
Email Dr. Charles Cywin to confirm.

Are you developing peptides, proteins, oligonucleotides, gene therapies, and cell therapies?

Do you meet the CREATE Bio Development criteria and align with the purpose of the FOA? (comparison: Optimization and Development Tracks)

 

Consider the U01 CREATE Bio Development program (PAR-18-542).
Consider the SBIR CREATE Bio Development program if you are eligible for SBIR (PAR-18-543).
Email Chris Boshoff regarding pre-application process. Refer to the CREATE Bio pre-application process webpage.

Email Chris Boshoff to determine if you fit the CREATE Bio program.
Do you want information on other options?

Do you meet the CREATE Bio Optimization criteria align with the purpose of the FOA? (comparison: Optimization and Development Tracks)

Consider the U01 CREATE Bio Optimization program (PAR-17-456).
Consider the SBIR CREATE Bio Optimization program (PAR-17-457) if you are eligible for SBIR.
Email Chris Boshoff regarding pre-application process. Refer to the CREATE Bio pre-application process webpage.

Consider the SBIR program. You are also eligible for the IGNITE Program.

Are you an SBIR program small business?

Consider the IGNITE Program.